Skip to main content
. Author manuscript; available in PMC: 2012 Jun 1.
Published in final edited form as: Cancer Res. 2011 Apr 18;71(11):3912–3920. doi: 10.1158/0008-5472.CAN-10-2259

Figure 2.

Figure 2

Flow cytometry data for L540 cell cycle effects of vorinostat and the AKi MK-0457 after forty-eight hours of treatment, assayed for DNA content by propidium iodide. Cell cycle profiles are shown for cells treated with A. DMSO. B. 1.5 μM vorinostat. C. 0.1 μM MK-0457. D. both drugs. Percentages of cells in each cycle stage are in listed in Supplementary Table 1.

HHS Vulnerability Disclosure